You are here

MK-5172

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

Motley Fool

Fri, 04/18/14 - 11:42 am

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Motley Fool

Tue, 04/15/14 - 10:36 am

Gilead Sciences

Bristol-Myers Squibb

Gilead Sciences: How Big a Threat is Merck?

Barron's

Thu, 04/10/14 - 10:52 am

Gilead Sciences

Merck Data Show Potent Rival to Gilead’s Hepatitis C Pill

Bloomberg

Thu, 04/10/14 - 07:39 am

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Yahoo/BusinessWire

Sat, 11/2/13 - 11:40 am

Big Pharma Fights Off the Dow's Drop

Motley Fool

Wed, 10/23/13 - 05:01 pm

Merck's Experimental Hepatitis C Drug Beats Victrelis

Bloomberg

Tue, 04/23/13 - 08:42 am

Merck, Bristol-Myers will test hepatitis C regimen

Yahoo/AP

Mon, 04/22/13 - 10:54 am

Bristol-Myers Squibb